Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Opportunities Hold Promise
Tweet
Share
E-mailGet Alerts GNMK Hot Sheet
Price: $24.04 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK) price target of $12.00.
Analyst, Jeffrey Frelick, said, "We reiterate our BUY on GNMK after recent management meetings highlight customer endorsements, technology advantages, and leadership progress...GNMK’s XT-8 (and NexGen) instrument platform offers advantages with its electronic measurement such as: multiplex capabilities (up to 72 markers), lower “no call” ratio due to less background noise, GM advantages due to low cost microchip reagents, and the ability to perform various types of molecular tests.
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $4.19 yesterday.
Analyst, Jeffrey Frelick, said, "We reiterate our BUY on GNMK after recent management meetings highlight customer endorsements, technology advantages, and leadership progress...GNMK’s XT-8 (and NexGen) instrument platform offers advantages with its electronic measurement such as: multiplex capabilities (up to 72 markers), lower “no call” ratio due to less background noise, GM advantages due to low cost microchip reagents, and the ability to perform various types of molecular tests.
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $4.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
